A breakthrough in pathology, achieved more than a century ago (allegedly on a frozen window ledge in Rochester, Minnesota) has evolved into an innovative aspect of care at Mayo Clinic.
Mayo Clinic is one of the only medical centers in the United States to routinely use a tissue-freezing process that provides analysis of tissue samples while the patient is still in the operating room. The procedure is particularly valuable for surgical resection of breast cancer, as it greatly increases the likelihood of full tumor removal in a single operation.
In modern breast-conserving surgery, the surgeon removes the cancerous lump and a margin of healthy tissue, while avoiding extensive removal of non-cancerous tissue. Later, a pathologist analyzes the tissue to determine if the cancer was fully removed. The pathologist’s report might require a week or more to complete. If it shows cancer at the margins of excised tissue, the patient must return for a second operation to remove the cancer.
“That happens in up to 40% of cases nationally. At Mayo Clinic, our rate of second surgeries to fully excise a tumor is 3%,” says Judy Boughey, M.D., a breast cancer surgeon at Mayo Clinic in Rochester, Minnesota.*
The difference is due to the Mayo Clinic Frozen Section Pathology Laboratory. At Mayo Clinic, after breast tissue is removed from a patient, it’s taken directly from the operating room to the nearby lab, where the edges around the lumpectomy are evaluated, and the sample is placed on a freezing machine known as a freezing microtome. The bottom of the sample is frozen within seconds. That allows the pathologist to extract a razor-thin slice for review under a microscope and convey the test results to the surgeon in the operating room within minutes—while the patient is still asleep. The surgeon can then remove more tissue if necessary, within a single operation.
“Our frozen section pathology is used routinely for intraoperative margin analysis in all breast cancer cases, not just those that might appear unusual,” says Elizabeth Habermann, Ph.D., Scientific Director of the Surgical Outcomes Program in the Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery.
“It’s a much smoother process,” Dr. Boughey adds.
“Without frozen tissue analysis, the patient goes home after breast surgery not knowing the size of the tumor, margin status, and whether the lymph nodes were involved, or what’s next. At Mayo, we can tell the patient the details about the tumor and lymph nodes, and discuss the next treatment steps after he or she wakes up.”
Specimens in the Frozen Section Pathology Laboratory subsequently undergo hematoxylin and eosin (known as H&E) stain analysis to double-check for cancer. “If there’s any change in diagnosis at that point, we consider whether further surgery is needed. That accounts for the 3% return rate,” Dr. Boughey says. “But frozen section analysis is the best real-time answer and almost a guarantee that the cancer was fully removed.”
Frozen section tissue analysis can lengthen breast surgery. “But in general, while the pathologist is looking at the margins using frozen section, the surgeon is continuing the surgery with removing the patient’s sentinel lymph nodes,” Dr. Boughey says. “We might even start closing the lumpectomy cavity. Once we hear back from the pathologist, if the margins are negative, we can wake up the patient there and then, so we haven’t prolonged surgery. Or, if the margins are positive, we can just cut out a couple stitches and re-excise that margin.”
In a published health economic analysis, Dr. Boughey and colleagues demonstrated that the use of frozen section tissue analysis in breast-conserving surgery would result in significant cost savings for Medicare, Medicaid, and private payers.** Although frozen section tissue analysis is costlier than standard analysis, the increase is offset by lower expenditures associated with avoiding reoperations.
As a result, if frozen section analysis were used in 20% of breast lumpectomies, the annual cost savings would be $18.2 million to payers and $400,000 to providers. If all facilities providing lumpectomies adopted the use of frozen section margin analysis, the potential annual cost savings would be $90.9 million to payers and $1.8 million to providers.
Another advantage of frozen tissue analysis is the opportunity it provides for pathologist and surgeon to confer about the tumor while the patient is still asleep. “Often the surgeon walks into the pathology lab and looks at the specimen with the pathology team while the patient is still in the operating room. That allows us to really see the disease,” Dr. Boughey says.
“If the margins are positive, when you return to the operating room, you can look at the lumpectomy cavity and know exactly whereabout you need to remove additional tissue.”